| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2011.11.026 |
| P698 | PubMed publication ID | 22119592 |
| P50 | author | John Edmunds | Q87928638 |
| P2093 | author name string | Albert Jan van Hoek | |
| Joke Bilcke | |||
| Alessia Melegaro | |||
| Nigel Gay | |||
| P2860 | cites work | The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003 | Q21257242 |
| Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study | Q28111909 | ||
| Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults | Q28111945 | ||
| Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox | Q28111950 | ||
| A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction | Q28112193 | ||
| A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults | Q28254168 | ||
| Incidence of Herpes Zoster, Before and After Varicella‐Vaccination–Associated Decreases in the Incidence of Varicella, 1992–2002 | Q28315859 | ||
| Social contacts and mixing patterns relevant to the spread of infectious diseases | Q28755323 | ||
| Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination | Q34158156 | ||
| Varicella vaccination in England and Wales: cost-utility analysis | Q34263829 | ||
| Economic evaluations of varicella vaccination programmes: a review of the literature | Q35026965 | ||
| An analysis of infection control of varicella-zoster virus infections in Addenbrooke's Hospital Cambridge over a 5-year period, 1987-92. | Q36504590 | ||
| Primary vaccine failure after 1 dose of varicella vaccine in healthy children | Q37131910 | ||
| Cost-effectiveness of varicella vaccination programs: an update of the literature | Q37229923 | ||
| Varicella prevention in the United States: a review of successes and challenges | Q37258047 | ||
| One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? | Q39133786 | ||
| Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States | Q40667632 | ||
| Modelling the impact of immunization on the epidemiology of varicella zoster virus | Q40722872 | ||
| Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England. | Q43836508 | ||
| Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. | Q43912397 | ||
| Changing varicella epidemiology in active surveillance sites--United States, 1995-2005. | Q44112725 | ||
| Ten year follow-up of healthy children who received one or two injections of varicella vaccine | Q44793181 | ||
| Incidence of herpes zoster, 1997-2002. | Q45057917 | ||
| Epidemiology of Varicella-Zoster Virus in England and Wales | Q45728840 | ||
| Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997-2005. | Q46083444 | ||
| Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes. | Q50660059 | ||
| Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. | Q51905646 | ||
| Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom | Q56768031 | ||
| The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination | Q84080724 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | herpes zoster | Q182155 |
| cost-effectiveness analysis | Q1754768 | ||
| P304 | page(s) | 1225-1234 | |
| P577 | publication date | 2011-11-23 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom | |
| P478 | volume | 30 |
| Q35151816 | Active learning to understand infectious disease models and improve policy making |
| Q49955021 | An ethics training specific for European public health |
| Q37521887 | Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting? |
| Q39128973 | Control of varicella in the post-vaccination era in Australia: a model-based assessment of catch-up and infant vaccination strategies for the future. |
| Q92593496 | Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model |
| Q47107085 | Cost-effectiveness of Varicella Vaccination Program in Iran. |
| Q34291150 | Cost-effectiveness of vaccination against herpes zoster |
| Q38188771 | Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review |
| Q37135445 | Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination |
| Q38542962 | Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review |
| Q36252698 | Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster |
| Q39550770 | Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5. |
| Q39549252 | Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--5. |
| Q40778022 | Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges. |
| Q35498396 | Evaluation of the economic burden of Herpes Zoster (HZ) infection |
| Q57482005 | Herpes zoster in the context of varicella vaccination - An equation with several variables |
| Q56879722 | How cost effective is universal varicella vaccination in developing countries? A case-study from Colombia |
| Q47583090 | Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used |
| Q56880767 | Intradermal zoster vaccines: good for the old and the young? |
| Q47549236 | Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway. |
| Q33683179 | Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox |
| Q27312388 | Negative attitude and low intention to vaccinate universally against varicella among public health professionals and parents in the Netherlands: two internet surveys |
| Q34683751 | Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries |
| Q47242634 | Post-herpetic neuralgia - a review of current management and future directions |
| Q38104665 | Progress in VZV vaccination? Some concerns |
| Q44749354 | Should the UK introduce a universal childhood varicella vaccination programme? |
| Q35652212 | Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. |
| Q36253248 | The 'Dynamic' Marriage Between Varicella and Zoster |
| Q57395637 | The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study |
| Q38761395 | Universal varicella vaccine immunization in Japan |
| Q26862748 | Vaccination against herpes zoster in developed countries: state of the evidence |
| Q47607699 | Varicella and herpes zoster vaccine development: lessons learned |
| Q41630514 | Varicella-zoster virus vaccination under the exogenous boosting hypothesis: two ethical perspectives |
| Q42273664 | Zostavax : a subcutaneous vaccine for the prevention of herpes zoster |
Search more.